Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorSun Yat-sen University
About this trial
This phase 2 trial studies the efficacy and safety of orelabrutinib plus rituximab followed by maintenance with orelabrutinib for relapsed and refractory follicular lymphoma(RR FL)
Eligibility criteria
Qualifiers
Histologically confirmed grade 1, 2, or 3A FL;
Patients received prior anti-lymphoma treatment;
At least one evaluable lesion according to 2014 Lugano criteria;
Age 18 years or older;
Disqualifiers
Patients who required warfarin or had a history of stroke or intracranial hemorrhage within 6 months, active transformed disease;
Histological transformation of follicular lymphoma;
Known central nervous system lymphoma;
Received a prior allogeneic hematopoietic stem cell transplant. Prior autologous hematopoietic stem cell transplant is allowed;
Trial design
Treatments tested in this trial
- Orelabrutinib and Rituximab
- Orelabrutinib
Treatment groups
32 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov